Rhythm (RYTM) Q2 Revenue Jumps 67%

Rhythm Pharmaceuticals (NASDAQ:RYTM), a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ($0.75). Increased operating expenses from research and development (R&D) and selling, general, and administrative (SG&A) costs drove this widening loss. Overall, the quarter reflected strong demand for IMCIVREE, the company’s approved treatment for rare MC4R pathway diseases, but also highlighted higher spending as Rhythm Pharmaceuticals advances its portfolio and global footprint. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Rhythm Pharmaceuticals develops therapies for rare genetic disorders of obesity, focusing on the melanocortin-4 receptor (MC4R) biological pathway. Its core product, IMCIVREE, is the first approved therapy for certain MC4R pathway diseases like Bardet-Biedl syndrome (BBS) and specific genetic obesity conditions. Led by setmelanotide, an MC4R agonist, the company’s pipeline also includes other drugs for additional rare forms of obesity and metabolic conditions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool